Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nuijten

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Nestle Nutrition Institute Workshop Series|November 7, 2015
Health Economics in Medical Nutrition: An Emerging ScienceMark Nuijten
Pharmacoeconomics|August 16, 2005
Incorporation of uncertainty in health economic modelling studiesMark Nuijten
Journal of Market Access & Health Policy|January 7, 2022
Pricing Zolgensma - the world's most expensive drugMark Nuijten
Clinical Therapeutics|May 4, 2010
A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspectiveMark Nuijten, Thomas Mittendorf
Journal of Market Access & Health Policy|August 28, 2024
Valuation of Medical Innovation Handling with Uncertainty and RiskMark Nuijten, Stefano Capri
Journal of Market Access & Health Policy|December 14, 2020
Pricing of orphan drugs in oncology and rare diseasesMark Nuijten, Stefano Capri
Journal of Market Access & Health Policy|June 13, 2022
An integrated valuation model for payer and investorMark Nuijten, Stefano Capri
European Journal of Pharmacology|August 4, 2011
Nutrition economics: an innovative approach to informed public health managementMark Nuijten, Irene Lenoir-Wijnkoop
BMC Health Services Research|March 13, 2021
The impact of early phase price agreements on prices of orphan drugsMark Nuijten, Philippe Van Wilder
Journal of Medical Economics|October 9, 2009
Cost effectiveness of palivizumab in children with congenital heart disease in GermanyMark Nuijten, Maximilian Lebmeier, Wolfgang Wittenberg
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Nestle Nutrition Institute Workshop Series|November 7, 2015
Health Economics in Medical Nutrition: An Emerging ScienceMark Nuijten
Pharmacoeconomics|August 16, 2005
Incorporation of uncertainty in health economic modelling studiesMark Nuijten
Journal of Market Access & Health Policy|January 7, 2022
Pricing Zolgensma - the world's most expensive drugMark Nuijten
Clinical Therapeutics|May 4, 2010
A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspectiveMark Nuijten, Thomas Mittendorf
Journal of Market Access & Health Policy|August 28, 2024
Valuation of Medical Innovation Handling with Uncertainty and RiskMark Nuijten, Stefano Capri
Journal of Market Access & Health Policy|December 14, 2020
Pricing of orphan drugs in oncology and rare diseasesMark Nuijten, Stefano Capri
Journal of Market Access & Health Policy|June 13, 2022
An integrated valuation model for payer and investorMark Nuijten, Stefano Capri
European Journal of Pharmacology|August 4, 2011
Nutrition economics: an innovative approach to informed public health managementMark Nuijten, Irene Lenoir-Wijnkoop
BMC Health Services Research|March 13, 2021
The impact of early phase price agreements on prices of orphan drugsMark Nuijten, Philippe Van Wilder
Journal of Medical Economics|October 9, 2009
Cost effectiveness of palivizumab in children with congenital heart disease in GermanyMark Nuijten, Maximilian Lebmeier, Wolfgang Wittenberg
Pageof 4